User Fees and Beyond — The FDA Safety and Innovation Act of 2012

Podobne knjige/članki

• FDA Approval of Cardiac Implantable Electronic Devices via Original and Supplement Premarket Approval Pathways, 1979-2012
  od: Rome, Benjamin N., et al.
  Izdano: (2014)
• FDA User Fees Gain Momentum
  od: Punzo, Christine
  Izdano: (1992)
• FDA Readies New Guidance and User Fee Program for Biosimilars: Drug interchangeability and user fees are contentious issues the FDA must resolve. Is the FDA up to the task?
  od: BARLAS, STEPHEN
  Izdano: (2012)
• Biosimilarity and Interchangeability in the Biologics Price Competition and Innovation Act of 2009 and FDA's 2012 Draft Guidance for Industry
  od: Koyfman, Hannah
  Izdano: (2013)
• The FDA’s Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016
  od: Hwang, Thomas J., et al.
  Izdano: (2017)